Unmet Needs and Efficacy Benchmarks in Nail Psoriasis

Nail psoriasis affects a significant proportion of patients with psoriasis, but it represents one of the disease's most challenging manifestations to manage effectively. Francisco Kerdel, MD, FAAD, of Florida Academic Dermatology Center, explains that topical agents are largely ineffective at the nail unit, historically pushing clinicians toward systemic therapies that were often toxic and inconsistently effective. For patients whose livelihood or daily interactions involve visible hands—or who experience significant distress from the appearance of affected nails—this unmet need has been profound.

A phase 3b trial addressed this gap by selecting patients specifically for nail involvement rather than extracting nail data from a broader psoriasis population. This design strengthened the study's clinical relevance. The primary end point of mNAPSI 75 (a 75% improvement in the modified Nail Psoriasis Severity Index) and the key secondary endpoint of ViSENPsO response were both met at week 28. Kerdel underscores that a 75% improvement in nail severity is clinically meaningful: given the complexity of evaluating multiple nails—some of which may achieve complete clearance while 1 or 2 lag behind—meeting this threshold reflects substantial benefit for patients.

Response rates continued to build beyond week 28, with more than 60% of initial responders maintaining improvement through week 52. Kerdel contextualizes this durability within the biology of nail growth: fingernails require approximately 6 months to grow fully, and toenails up to 18 months, so patience is essential when setting treatment expectations. Even highly efficacious agents cannot accelerate nail regeneration.

Through week 72, no new safety signals emerged. Kerdel views this data package as compelling evidence that tildrakizumab fits meaningfully into the treatment algorithm for patients whose nail psoriasis is a primary driver of disease burden.